| PRKN — Parkin RBR E3 Ubiquitin Protein Ligase | |
|---|---|
| Symbol | PRKN |
| Full Name | Parkin RBR E3 Ubiquitin Protein Ligase |
| Chromosome | 6q26 |
| NCBI Gene | 5071 |
| Ensembl | ENSG00000185345 |
| OMIM | 602544 |
| UniProt | O60260 |
| Diseases | Parkinson's Disease |
| Expression | Substantia nigra, Cerebral cortex, Widespread |
| Key Mutations | |
| Exon deletions, R42P, K211N, T240R, C431F, C418G, R275W, R256C | |
Prkn — Parkin Rbr E3 Ubiquitin Protein Ligase is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PRKN (Parkin RBR E3 Ubiquitin Protein Ligase), also known as PARK2, is a gene located on chromosome 6q26 that encodes the Parkin protein, an E3 ubiquitin ligase essential for mitochondrial quality control[1]. Mutations in PRKN cause autosomal recessive juvenile-onset Parkinson's Disease, representing one of the most common forms of early-onset PD[2]. The discovery of PRKN mutations as a cause of PD in 1998 was landmark in understanding the role of protein degradation and mitophagy in neurodegeneration.
The protein encoded by PRKN is [Parkin--TEMP--/proteins)--FIX--, a 465-amino acid protein with RING-between-RING (RBR) architecture. See the protein page for detailed structural and functional information.
The PRKN gene spans approximately 1.4 Mb of genomic DNA on chromosome 6q26 and consists of 12 exons[3]. The gene produces multiple alternatively spliced isoforms with tissue-specific expression.
The PRKN promoter contains several regulatory elements:
Expression is regulated by:
In the healthy brain, PRKN is expressed at high levels in:
PRKN is ubiquitously expressed in all tissues. Expression data is available from the Allen Human Brain Atlas.
Parkin plays several essential roles in cellular homeostasis:
PRKN mutations cause autosomal recessive PD through loss of function[4]:
Most pathogenic mutations result in:
The sequence of events in PRKN-linked PD:
| Mutation | Type | Effect |
|---|---|---|
| Exon deletions | Deletion | Loss of function |
| R42P | Missense | Disrupted RING0 domain |
| K211N | Missense | Impaired ubiquitin binding |
| T240R | Missense | Reduced activity |
| C431F | Missense | RING2 domain disruption |
| C418G | Missense | Impaired catalysis |
| R275W | Missense | Reduced ligase activity |
| R256C | Missense | Altered substrate recognition |
Parkin and PINK1 work together in the mitochondrial quality control pathway[5]:
Parkin ubiquitinates numerous substrates:
Several models have been developed:
Current research focuses on:
The study of Prkn — Parkin Rbr E3 Ubiquitin Protein Ligase has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605-608. DOI:10.1038/33434
[2] Lücking CB, Dürr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med. 2000;342(21):1560-1567.
[3] Hristova VA, Beasley SA, Rylett RJ, Shaw GS. A novel in-frame deletion in the RING0 domain of Parkin associated with early onset Parkinson's disease. Neurosci Lett. 2009;462(2):171-175.
[4] Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol. 2008;183(5):795-803.
[5] Kazlauskaite A, Kondapalli C, Gourlay R, et al. Phosphorylation of Parkin at Serine65 is essential for activation. Biochem J. 2014;462(3):e1-e3.
[6] Zhang C, Lin D, Wu Y, et al. Parkin deficiency contributes to lipid accumulation through impaired lipophagy. Cell Death Dis. 2020;11(7):550.